Skip Navigation


JAC Advance Access originally published online on April 11, 2005
Journal of Antimicrobial Chemotherapy 2005 55(6):950-953; doi:10.1093/jac/dki111
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
55/6/950    most recent
dki111v2
dki111v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Guna, R.
Right arrow Articles by Borrás, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Guna, R.
Right arrow Articles by Borrás, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published by Oxford University Press 2005.

In vitro activity of linezolid, clarithromycin and moxifloxacin against clinical isolates of Mycobacterium kansasii

Remedios Guna1,2, Carlos Muñoz1, Victoria Domínguez1, Ángeles García-García2, Jorge Gálvez2, Jesús-Vicente de Julián-Ortiz2 and Rafael Borrás1,*

1 Departamento de Microbiología, Facultad de Medicina y Hospital Clínico Universitario, Universidad de Valencia, Av. Blasco Ibáñez 17, 46010 Valencia, Spain; 2 Unidad de Investigación de Diseño de Fármacos y Conectividad Molecular, Departamento de Química Física, Facultad de Farmacia, Universidad de Valencia, 46100 Burjassot, Valencia, Spain

* Corresponding author. Fax: +34-963-987-836; Email: rafael.borras{at}uv.es

Objectives: To compare the activity of linezolid with a range of drugs used in the treatment of Mycobacterium kansasii infections.

Results: The percentages of resistant isolates against isoniazid, rifampicin and ethambutol were 2.9%, 1.9% and 2.9%, respectively. All isolates were susceptible to clarithromycin and moxifloxacin both with MIC90 values of 0.125 mg/L. Linezolid was active against all isolates with MIC50 and MIC90 values of 0.5 and 1 mg/L, respectively, both below the susceptibility breakpoint established for mycobacteria.

Conclusion: Linezolid, clarithromycin or moxifloxacin, could be used as alternative drugs for treatment of infections due to rifampicin-resistant isolates as well as short-course or intermittent therapy of M. kansasii lung disease.

Keywords: non-tuberculous mycobacteria , antimycobacterial agents , broth microdilution method


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur Respir JHome page
M. Santin, J. Dorca, F. Alcaide, L. Gonzalez, S. Casas, M. Lopez, and M. R. Guerra
Long-term relapses after 12-month treatment for Mycobacterium kansasii lung disease
Eur. Respir. J., January 1, 2009; 33(1): 148 - 152.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.